ARCHIVES

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

NCI Intends To Extend OSCC Two More Years

October 3, 1986

Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas

December 28, 2012

M.D. Anderson Closes Trials following FDA Requests for Data

February 16, 1996

Professional Societies: AACR To Establish A Foundation To fund Outreach, Education

April 23, 1999

Proposed HHS Conflict of Interest Rules May Require More Disclosure by Researchers

May 15, 2009

Hiring Freeze Squeezes NIH, NCI

August 3, 1979